Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 2
1986 2
1987 2
1988 9
1989 6
1990 42
1991 13
1992 14
1993 25
1994 20
1995 18
1996 21
1997 37
1998 42
1999 28
2000 38
2001 44
2002 33
2003 23
2004 33
2005 23
2006 29
2007 24
2008 22
2009 28
2010 30
2011 32
2012 20
2013 25
2014 25
2015 15
2016 11
2017 17
2018 23
2019 12
2020 25
2021 15
2022 10
2023 9
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

806 results

Results by year

Filters applied: . Clear all
Page 1
Toremifene.
[No authors listed] [No authors listed] IARC Monogr Eval Carcinog Risks Hum. 1996;66:367-87. IARC Monogr Eval Carcinog Risks Hum. 1996. PMID: 9097128 Free PMC article. Review. No abstract available.
Breast pain.
Goyal A. Goyal A. BMJ Clin Evid. 2011 Jan 17;2011:0812. BMJ Clin Evid. 2011. PMID: 21477394 Free PMC article. Review.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: antibiotics, bromocriptine, combined oral contraceptive pill, danazol, diuretics, evening primrose oil, gestrinone, gonadorelin analogues, hormon …
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: antib …
Experimental adenomyosis.
Greaves P, White IN. Greaves P, et al. Best Pract Res Clin Obstet Gynaecol. 2006 Aug;20(4):503-10. doi: 10.1016/j.bpobgyn.2006.01.003. Epub 2006 Feb 23. Best Pract Res Clin Obstet Gynaecol. 2006. PMID: 16500151 Review.
Its incidence in mice can be markedly enhanced by systemic exposure to various hormonal agents, including prolactin, progesterone, synthetic progestins, certain oestrogenic agents, as well as tamoxifen and toremifene. The precise hormonal changes necessary remain unclear, …
Its incidence in mice can be markedly enhanced by systemic exposure to various hormonal agents, including prolactin, progesterone, synthetic …
Phase II and III clinical trials of toremifene for metastatic breast cancer.
Vogel CL. Vogel CL. Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):9-13. Oncology (Williston Park). 1998. PMID: 9556785 Free article. Review.
Toremifene (Fareston) received FDA approval in 1997 for the first-line treatment of postmenopausal women with estrogen receptor (ER)-positive or -unknown metastatic breast cancer. ...To date, phase III trials have failed to show a statistically significant advantage of hig …
Toremifene (Fareston) received FDA approval in 1997 for the first-line treatment of postmenopausal women with estrogen receptor (ER)- …
Breast pain.
Bundred NJ. Bundred NJ. BMJ Clin Evid. 2007 Apr 1;2007:0812. BMJ Clin Evid. 2007. PMID: 19454068 Free PMC article. Review.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: a low-fat diet, antibiotics, bromocriptine, danazol, diuretics, evening primrose oil, gestrinone, gonadorelin analogues, hormone replacement ther …
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: a low …
Toxicity of antiestrogens.
Hirsimäki P, Aaltonen A, Mäntylä E. Hirsimäki P, et al. Breast J. 2002 Mar-Apr;8(2):92-6. doi: 10.1046/j.1524-4741.2002.08204.x. Breast J. 2002. PMID: 11896754 Review.
The object of this article is to review briefly the preclinical and clinical safety of some antiestrogens. Tamoxifen, toremifene, droloxifene, and idoxifene are polyphenylethylene antiestrogens, whereas the pure antiestrogen, ICI 182,780 or faslodex, as well as raloxifene, …
The object of this article is to review briefly the preclinical and clinical safety of some antiestrogens. Tamoxifen, toremifene, dro …
Clinical pharmacokinetics of toremifene.
Taras TL, Wurz GT, Linares GR, DeGregorio MW. Taras TL, et al. Clin Pharmacokinet. 2000 Nov;39(5):327-34. doi: 10.2165/00003088-200039050-00002. Clin Pharmacokinet. 2000. PMID: 11108432 Review.
Oral bioavailability is estimated to be approximately 100%. At steady state, toremifene and its metabolites are highly protein bound (>95%). Toremifene is metabolised in the liver by cytochrome P450 enzymes, and it is eliminated primarily in the faeces following …
Oral bioavailability is estimated to be approximately 100%. At steady state, toremifene and its metabolites are highly protein bound …
Introduction to toremifene.
Kangas L. Kangas L. Breast Cancer Res Treat. 1990 Aug;16 Suppl:S3-7. doi: 10.1007/BF01807138. Breast Cancer Res Treat. 1990. PMID: 2149282 Review.
Toremifene, a triphenylethylene antiestrogen first synthesized in 1981, binds to the estrogen receptor with an affinity about 5% that of estradiol. ...It has a long elimination half-life and there are several metabolites, but the principal antitumor activity appears to be …
Toremifene, a triphenylethylene antiestrogen first synthesized in 1981, binds to the estrogen receptor with an affinity about 5% that …
RETIRED: Mastalgia.
Rosolowich V, Saettler E, Szuck B; BREAST DISEASE COMMITTEE. Rosolowich V, et al. J Obstet Gynaecol Can. 2006 Jan;28(1):49-57. doi: 10.1016/S1701-2163(16)32027-8. J Obstet Gynaecol Can. 2006. PMID: 16533457 English, French.
Adjuvant trials of toremifene vs tamoxifen: the European experience.
Holli K. Holli K. Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):23-7. Oncology (Williston Park). 1998. PMID: 9556787 Free article. Review.
When results from the phase II trials of toremifene (Fareston) and tamoxifen (Nolvadex) in metastatic breast cancer were published, the Finnish Breast Cancer Group began to plan the first trial of toremifene in an adjuvant setting. ...The effects of toremifene …
When results from the phase II trials of toremifene (Fareston) and tamoxifen (Nolvadex) in metastatic breast cancer were published, t …
806 results